Saturday 17 October 2026
Export IPHA’s income statement to Excel — free account
Innate Pharma S.A. Sponsored ADR
IPHA Healthcare Biotechnology
Innate Pharma S.A. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $10.2 million, down 53.2% from fiscal 2024.
1.43
0.05
−3.38%
Follow IPHA
Innate Pharma S.A. Sponsored ADR (IPHA) P/E ratio
Innate Pharma S.A. Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 251× (May 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 197× | 1,907.83% |
| FY2018 | 9.8× | 0.00% |
| FY2017 | 9.8× | 0.00% |
| FY2016 | 9.8× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2023 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| Dec 2021 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
Low 0.0×
High 251×
Ten-year median
0.0×
Current reading's percentile
90
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CMPX Compass Therapeutics, Inc. compare | n/m |
| ADAG Adagene Inc. Sponsored ADR compare | n/m |
| WHWK Whitehawk Therapeutics, Inc. compare | n/m |
| MDWD MediWound Ltd. compare | n/m |
| CHRS Coherus Oncology, Inc. compare | n/m |
| IPHA Innate Pharma S.A. Sponsored ADR | n/m |
| DTIL Precision BioSciences, Inc. compare | n/m |
| ORMP Oramed Pharmaceuticals Inc. compare | 1.0× |
| VRXA Veraxa Biotech AG compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)